Pregnancy Outcomes in Maternal Neuropsychiatric Illness and Substance Abuse

Abstract

Introduction Worldwide the prevalence of neuropsychiatric illness among women of reproductive age is higher than ever before. This study investigates the influences of maternal substance abuse/dependence and neuropsychiatric illness on pregnancy and neonatal outcomes.

Patients and Methods Using a retrospective study design 185 pregnancies in women with neuropsychiatric illnesses or substance abuse were identified at a single centre over a period of 3.25 years and compared to 4907 pregnancies in healthy women without mental illness. Differences in pre-, peri- and postnatal pregnancy parameters were studied.

Results Numbers of previous abortions on obstetric history were significantly higher in cases compared to controls, women with depression being especially affected. The number of antenatal visits was also higher among cases, especially in women with depression. The caesarean section rate was significantly higher in cases compared to controls. Children of women with neuropsychiatric illness were born at lower gestational ages than those of healthy control mothers, however there were no significant differences between case and control groups for birth weight, head circumference or Apgar scores. Some isolated differences were found for disease-specific case subgroups compared to controls.

Conclusion The study shows a relationship between maternal neuropsychiatric illness and pregnancy outcomes independent of medication use. Rates of spontaneous abortion were higher. Children were born earlier, yet the neonatal outcomes birth weight, head circumference and Apgar score were not worse than children of mentally healthy women.

Key words

pregnancy outcome - neuropsychiatric illness - abortion - fetal outcome - pregnancy

• References/Literatur

• 1 Ruscio AM, Hallion LS, Lim CCW. et al. Cross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe. JAMA Psychiatry 2017; 74: 465-475
• 2 Busch MA, Maske UE, Ryl L. et al. Prävalenz von depressiver Symptomatik und diagnostizierter Depression bei Erwachsenen in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2013; 56: 733-739
• 3 Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020. Global Burden of Disease Study. Lancet 1997; 349: 1498-1504
• 4 Jacobi F, Hofler M, Siegert J. et al. Twelve-month prevalence, comorbidity and correlates of mental disorders in Germany: the Mental Health Module of the German Health Interview and Examination Survey for Adults (DEGS1-MH). Int J Methods Psychiatr Res 2014; 23: 304-319
• 5 Hand DJ, Short VL, Abatemarco DJ. Treatments for opioid use disorder among pregnant and reproductive-aged women. Fertil Steril 2017; 108: 222-227
• 6 Gopman S. Prenatal and postpartum care of women with substance use disorders. Obstet Gynecol Clin North Am 2014; 41: 213-228
• 7 Keegan J, Parva M, Finnegan M. et al. Addiction in pregnancy. J Addict Dis 2010; 29: 175-191
• 8 Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723-1733
• 9 Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007; 27: 607-613
• 10 Vigod SN, Kurdyak PA, Dennis CL. et al. Maternal and newborn outcomes among women with schizophrenia: a retrospective population-based cohort study. BJOG 2014; 121: 566-574
• 11 Grunwald L, Jorch G, Kropf S. et al. Die Bedeutung neurologischer, psychiatrischer und Suchterkrankungen für den Schwangerschaftsausgang: Fall-Kontroll-Studie der Geburtsjahrgänge 2010–2012. Zeitschrift für Geburtshilfe und Neonatologie 2016; 220: 116-123
• 12 Le Strat Y, Dubertret C, Le Foll B. Prevalence and correlates of major depressive episode in pregnant and postpartum women in the United States. J Affect Disord 2011; 135: 128-138
• 13 Ulrich F, Petermann F. Consequences and possible predictors of health-damaging behaviors and mental health problems in pregnancy – a review. Geburtsh Frauenheilk 2016; 76: 1136-1156
• 14 Gelaye B, Rondon MB, Araya R. et al. Epidemiology of maternal depression, risk factors, and child outcomes in low-income and middle-income countries. Lancet Psychiatry 2016; 3: 973-982
• 15 Harden CL, Hopp J, Ting TY. et al. Practice parameter update: management issues for women with epilepsy–focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73: 126-132
• 16 Kolte AM, Olsen LR, Mikkelsen EM. et al. Depression and emotional stress is highly prevalent among women with recurrent pregnancy loss. Hum Reprod 2015; 30: 777-782
• 17 Nybo Andersen AM, Wohlfahrt J, Christens P. et al. Maternal age and fetal loss: population based register linkage study. BMJ 2000; 320: 1708-1712
• 18 Hoog SL, Cheng Y, Elpers J. et al. Duloxetine and pregnancy outcomes: safety surveillance findings. Int J Med Sci 2013; 10: 413-419
• 19 Kulin NA, Pastuszak A, Sage SR. et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609-610
• 20 Bellantuono C, Orsolini L, Bozzi F. La sicurezza dellʼescitalopram in gravidanza e nellʼallattamento. Riv Psichiatr 2013; 48: 407-414
• 21 Andrade C. The safety of duloxetine during pregnancy and lactation. J Clin Psychiatry 2014; 75: e1423-e1427
• 22 Zhang D, Shi W, Li C. et al. Risk factors for recurrent ectopic pregnancy: a case-control study. BJOG 2016; 123 (Suppl. 03) 82-89
• 23 Muller V, Makhmadalieva M, Kogan I. et al. Ectopic pregnancy following in vitro fertilization: meta-analysis and single-center experience during 6 years. Gynecol Endocrinol 2016; 32 (Suppl. 02) 69-74
• 24 Spain J, Rheinboldt M. MDCT of pelvic inflammatory disease: a review of the pathophysiology, gamut of imaging findings, and treatment. Emerg Radiol 2017; 24: 87-93
• 25 Reddy UM, Davis JM, Ren Z. et al. Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. Obstet Gynecol 2017; 130: 10-28
• 26 Rusner M, Berg M, Begley C. Bipolar disorder in pregnancy and childbirth: a systematic review of outcomes. BMC Pregnancy Childbirth 2016; 16: 331
• 27 Ross LE, Grigoriadis S, Mamisashvili L. et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 2013; 70: 436-443
• 28 Hoirisch-Clapauch S, Brenner B, Nardi AE. Adverse obstetric and neonatal outcomes in women with mental disorders. Thromb Res 2015; 135: 60-63
• 29 Bennett AD. Perinatal substance abuse and the drug-exposed neonate. Adv Nurse Pract 1999; 7: 32-36 quiz 37–38
• 30 Li D, Liu L, Odouli R. Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Hum Reprod 2009; 24: 146-153
• 31 Field T. Prenatal depression effects on early development: a review. Infant Behav Dev 2011; 34: 1-14
• 32 Chiriboga CA. Fetal alcohol and drug effects. Neurologist 2003; 9: 267-279
• 33 Covington CY, Nordstrom-Klee B, Ager J. et al. Birth to age 7 growth of children prenatally exposed to drugs: a prospective cohort study. Neurotoxicol Teratol 2002; 24: 489-496
• 34 Pinto TM, Caldas F, Nogueira-Silva C. et al. Maternal depression and anxiety and fetal-neonatal growth. J Pediatr (Rio J) 2017; 93: 452-459
• 35 Sutter-Dallay AL, Bales M, Pambrun E. et al. Impact of prenatal exposure to psychotropic drugs on neonatal outcome in infants of mothers with serious psychiatric illnesses. J Clin Psychiatry 2015; 76: 967-973
• 36 Diego MA, Field T, Hernandez-Reif M. et al. Prenatal depression restricts fetal growth. Early Hum Dev 2009; 85: 65-70
• 37 Viale L, Allotey J, Cheong-See F. et al. Epilepsy in pregnancy and reproductive outcomes: a systematic review and meta-analysis. Lancet 2015; 386: 1845-1852
• 38 Hollins K. Consequences of antenatal mental health problems for child health and development. Curr Opin Obstet Gynecol 2007; 19: 568-572
• 39 Addis A, Moretti ME, Ahmed Syed F. et al. Fetal effects of cocaine: an updated meta-analysis. Reprod Toxicol 2001; 15: 341-369
• 40 van Tong T, Farr SL, Bombard J. et al. Smoking before and during pregnancy among women reporting depression or anxiety. Obstet Gynecol 2016; 128: 562-570
• 41 Cantarutti A, Merlino L, Monzani E. et al. Is the risk of preterm birth and low birth weight affected by the use of antidepressant agents during pregnancy? A population-based investigation. PLoS One 2016; 11: e0168115